Ryan Daws

Ryan Daws

Chief Financial OfficeratenGene Therapeutics· In the 2025 proxy

Pay in FY2025enGene Therapeutics stock -18.5% the same year

Ryan Daws was paid $2.2M in FY2025 (Oct). enGene Therapeutics stock fell 18.5% that year.

Pay$100 in the stock at the end of FY24 → $81
Pay is from the Summary Compensation Table of each enGene Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. enGene TherapeuticsPublic company · 1 yr
    • Chief Financial Officer2025 – Present · 1 yrStock in role -82%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?